Ed Yardeni, Yardeni Research president, discusses how he sees next month's election playing out in the markets.
Arie Belldegrun, Kite Pharma CEO talks to CNBC's Meg Tirrell about developing cancer immunotherapy drugs with T-cells. Also Belldegrun address the question about pricing the product once it comes to market.
Martin Shkreli heads back to court to face charges of looting his former biotech firm and pay back defrauded investors, reports CNBC's Meg Tirrell.
The "Fast Money Halftime Report" traders, Kevin O'Leary, O'Shares Chairman and "Shark Tank" star, and Ian Winer, Wedbush, share their takes on the health care sector, including Merck after Bank of America's call to upgrade the stock to buy.
CNBC's Bertha Coombs reports the latest troubles in health care, including why shares of Humana are sinking.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
CNBC's Meg Tirrell discusses the latest moves in health care, and how politics is weighing on the sentiment in the space.
John Crowley, CEO of Amicus Therapeutics, discusses his biotechnology business model, as well as drugs pricing.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
The "Fast Money" traders discuss the trade on biotech stocks, with healthcare being the worst-performing sector today.
Michael Yee, RBC Capital Markets biotech analyst, shares his take on big biotech movers including Mylan, Tesaro and more.
CNBC's Meg Tirrell reports the latest in biotech, including what is next for Mylan following the company's EpiPen settlement with the U.S. Department of Justice.
CNBC's Meg Tirrell reports on why billions are at stake for Bristol-Myers and Merck. The “Fast Money” traders weigh in.
Acute flaccid myelitis (AFM) — a mysterious muscle weakness, similar to polio — appears to be on the rise this year, reports NBC.
The "Fast Money Halftime Report" traders; Rob Sechan, UBS managing director; and Adam Parker, Morgan Stanley U.S. chief equity strategist, share their fourth quarter game plans.
The key biotechnology ETF fell more than 3 percent on Thursday.
Discussing why options traders are cautious about Teva Pharmaceuticals with CNBC contributor Mike Khouw.
Biotech stocks are under pressure as California proposes a "Drug Price Relief Act" to curb the high cost of drugs after Mylan's EpiPen controversy. The "Fast Money" traders share their views on the biotech sector.
Lawmakers are venting outrage over high prescription drug costs, but members might want to look in the mirror, NBC News reports.
Intra-Cellular Therapies shares plunge 68 percent after study results on a schizophrenia drug trial. CNBC's Seema Mody reports.